There is a rising global incidence of diabetes where progressive diabetic kidney disease (DKD) seen in 25–40% of individuals, is a major factor driving mortality risk1. Inhibitors of the renin-angiotensin system are first line therapies administered upon clinical presentation of DKD2. Although rec...